Patent application number | Description | Published |
20100285477 | Method for Predicting the Response to a Therapy - The invention concerns an in vitro method for selecting the therapy for a steroid resistant patient, wherein the method comprises isolating cells from a sample taken from said patient; cultivating said isolated cells in the presence of a steroid, an immunomodulatory oligonucleotide or a mixture thereof; determining an expression level of at least one marker gene in said isolated cells; and comparing said expression level of said at least one marker gene to a value obtained from the cultivation of cells from a healthy person in the presence of a steroid, an immunomodulatory oligonucleotide or a mixture thereof, or to a normalized value obtained from a healthy population. Examples of marker genes are CD163, Tsp1, IL1-R2, TLR2, TLR4, MKP-1 and TXK. | 11-11-2010 |
20110183337 | Method and Kit for Use in the Differentiation of IBD and IBS and Further Distinction Between Disease Types of IBD - A quantification of the expression levels of a number of specific genes and their corresponding proteins can be utilized in accurately determining, using samples from faeces or blood, whether the patient is suffering from irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD), and in a follow up analysis using a biopsy, determine if the same patient is afflicted with ulcerative colitis (UC) or Crohn's disease (CD). The method also has utility in determining the severity of the disease, as well as observing a patient's response to treatment. | 07-28-2011 |
20110293702 | Compounds and Methods for the Treatment of Inflammatory Diseases of the CNS - Inflammatory diseases in the CNS can be treated or alleviated by the administration of an oligonucleotide in an amount sufficient to reduce the influx of mononuclear cells to the central nervous system by down-regulating the expression of at least one cell surface marker. For example multiple sclerosis can be treated or at least alleviated, by the administration of an oligonucleotide in a dose effective to inhibit or reduce the influx of mononuclear and/or autoaggressive cells to the central nervous system. The oligonucleotide can be used alone, or in combination with other treatment strategies. | 12-01-2011 |
20140030723 | Method for Predicting the Response to a Therapy - A test kit for selecting a therapy for a steroid resistant patient presenting inflammatory symptoms comprises primer pairs or antibodies specific for at least one marker gene or protein translated from at least one marker gene, and instructions for use. The primer pairs or antibodies enable analysis of expression level of the at least one marker gene or translated protein from the at least one marker gene. | 01-30-2014 |
20140128456 | Compounds and methods for the treatment of inflammatory diseases of the CNS - Inflammatory diseases in the CNS can be treated or alleviated by the administration of an oligonucleotide in an amount sufficient to reduce the influx of mononuclear cells to the central nervous system by down-regulating the expression of at least one cell surface marker. For example multiple sclerosis can be treated or at least alleviated, by the administration of an oligonucleotide in a dose effective to inhibit or reduce the influx of mononuclear and/or autoaggressive cells to the central nervous system. The oligonucleotide can be used alone, or in combination with other treatment strategies. | 05-08-2014 |
Patent application number | Description | Published |
20080207930 | Process For Producing a Chlorhydrin From a Multihydroxylated Aliphatic Hydrocarbon and/or Ester Thereof in the presence of Metal Salts - Process for producing a chlorohydrin by reaction between a multihydroxylated-aliphatic hydrocarbon, an ester of a multihydroxylated-aliphatic hydrocarbon, or a mixture thereof, and a chlorinating agent, according to which the multihydroxylated-aliphatic hydrocarbon, the ester of a multihydroxylated-aliphatic hydrocarbon, or the mixture thereof used contains at least one solid or dissolved metal salt, the process comprising a separation operation to remove at least part of the metal salt. | 08-28-2008 |
20120010420 | PROCESS FOR PRODUCING AN ORGANIC COMPOUND - Process for producing a chlorohydrin by reaction between a multihydroxylated-aliphatic hydrocarbon, an ester of a multihydroxylated-aliphatic hydrocarbon, or a mixture thereof, and a chlorinating agent, according to which the multihydroxylated-aliphatic hydrocarbon, the ester of a multihydroxylated-aliphatic hydrocarbon, or the mixture thereof used contains at least one solid or dissolved metal salt, the process comprising a separation operation to remove at least part of the metal salt. | 01-12-2012 |
Patent application number | Description | Published |
20130164797 | PROCESS FOR THE IMPROVED SEPARATION OF A HYDROPHOBIC ORGANIC SOLUTION FROM AN AQUEOUS CULTURE MEDIUM - A process for the improved separation of a hydrophobic organic solution from an aqueous culture medium is provided. The process includes preparing an aqueous culture medium of a metabolically active cell having a decreased activity; contacting of the aqueous culture medium with a hydrophobic organic solution comprising a substrate for biotransformation; conducting a biotransformation of the substrate; and separating the hydrophobic organic solution comprising a biotransformed substrate from the aqueous culture medium. The decreased activity of the metabolically active cell is in comparison to a wild-type of the active cell and the decreased activity is of at least of one enzyme that catalyses one reaction of β-oxidation of fatty acids. The invention further provides a metabolically active cell that has a decreased activity, compared to its wild-type, of an enzyme that catalyses one of the reactions of the β-oxidation of fatty acids, including an enzyme selected from FadA, FadB, FadD, FadL and FadE as well as variants thereof. | 06-27-2013 |
20140178948 | PRODUCTION OF OMEGA-AMINO FATTY ACIDS - The invention provides a whole cell catalyst which expresses a recombinant α-dioxygenase or the combination of a recombinant fatty acid reductase and a phosphopantetheinyl transferase phosphopantetheinylating the fatty acid reductase, and which in addition to the α-dioxygenase and/or the combination of fatty acid reductase and phosphopantetheinyl transferase expresses a transaminase, characterized in that the phosphopantetheinyl transferase and/or transaminase is preferably recombinant; and a method for the conversion of a fatty acid, ω-hydroxy fatty acid, ω-oxo fatty acid or a monoester thereof to an amine, comprising oxidation of the fatty acid, ω-hydroxy fatty acid, ω-oxo fatty acid or the monoester thereof to an oxidation product by contacting with an alkane hydroxylase and/or alcohol dehydrogenase, contacting the oxidation product with a phosphopantetheinylated fatty acid reductase or a α-dioxygenase to give an aldehyde, and contacting the aldehyde with a transaminase. | 06-26-2014 |
20140186905 | BIOTECHNOLOGICAL SYNTHESIS PROCESS OF ORGANIC COMPOUNDS WITH THE AID OF AN ALKL GENE PRODUCT - Subject matter of the invention is a biotechnological process for the production of organic compounds with the aid of at least one alkL gene product. | 07-03-2014 |
20140256904 | BIOTECHNOLOGICAL SYNTHESIS PROCESS OF OMEGA-FUNCTIONALIZED CARBON ACIDS AND CARBON ACID ESTERS FROM SIMPLE CARBON SOURCES - The subject of the invention is a biotechnological process for the production of ω-functionalized carboxylic acids and of ω-functionalized carboxylate esters from simple carbon sources. | 09-11-2014 |
Patent application number | Description | Published |
20090162904 | TRANSGENIC PLANTS AND METHODS FOR CONTROLLING BOLTING IN SUGAR BEET - This invention relates to the field of sugar beet bolting and flowering control, specifically methods and transgenic sugar beet plants for suppressing the vernalization response. In particular, the present invention includes sugar beet plants and methods for modulating sugar beet vernalization by over expression of an FLC gene or by suppressing AGL20 gene expression. | 06-25-2009 |
20090205073 | TRANSGENIC PLANTS AND METHODS FOR CONTROLLING BOLTING IN SUGAR BEET - This invention relates to the field of sugar beet bolting and flowering control, specifically methods and transgenic sugar beet plants for suppressing the vernalization response. In particular, the present invention includes sugar beet plants and methods for modulating sugar beet vernalization by over expression of an FLC gene or by suppressing AGL20 gene expression. | 08-13-2009 |
20100209919 | POLYNUCLEOTIDE MARKERS - The invention relates to polynucleotides that are closely linked to the bolting gene or B gene within the sugar beet genome and can be used for the development of molecular markers. The invention further relates to molecular markers and kits comprising said markers that can be used for mapping, identification and isolation of the bolting gene or S gene in the sugar beet genome and to discriminate between the annual and bienniai genotype or between different haplotypes within plant groupings of sugar beet plants exhibiting a biennial genotype. The invention also relates to assays and methods of breeding sugar beet plants involving said markers. | 08-19-2010 |
20110138492 | TRANSGENIC SUGAR BEET PLANTS - The invention relates to transgenic sugar beet plants having a phenotype of delayed bolting. The invention further relates to polynucleotides that are closely linked to the bolting gene or B gene within the sugar beet genome and can be used for the discrimination between the annual and biennial genotype or between different haplotypes within plant groupings of sugar beet plants exhibiting a biennial genotype. | 06-09-2011 |
20110231946 | ENGINEERING OF BOLTING RESISTANCE IN SUGAR BEET BY MEANS OF THE TRANSGENIC EXPRESSION OF THE BEET HOMOLOGUE OF FLOWERING TIME CONTROL GENE FT - This invention relates to the field of bolting and flowering time control in sugar beet, specifically to methods as well as nucleic acid molecules, chimeric constructs, and vectors for engineering bolting resistance in sugar beet by means of altering the expression of the | 09-22-2011 |
20120144516 | TRANSGENIC SUGAR BEET EVENT GM RZ13 - A novel transgenic sugar beet event designated GM RZ13 is disclosed. The invention relates to nucleic acids that are unique to event GM RZ13. The invention also relates to assays for detecting the presence of the GM RZ13 event based on DNA sequences of the recombinant constructs inserted into the sugar beet genome that resulted in the GM RZ13 event and of genomic sequences flanking the insertion site. The invention further relates to sugar beet plants comprising the genotype of GM RZ13 and to methods for producing a sugar beet plant by crossing a sugar beet plant comprising the GM RZ13 genotype with itself or another sugar beet variety. Seeds of sugar beet plants comprising the GM RZ13 genotype are also objects of the present invention. | 06-07-2012 |